Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.

Geoerger B, Moreno L, Bouffet E, Upadhyaya SA, André N, Aerts I, Plant-Fox AS, Roughton M, Russo M, Hargrave D

Open source

DOI
10.1093/nop/npaf061
Published
2025 Dec
Container
Neuro-oncology practice
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/nop/npaf061,
  title = {Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.},
  author = {Geoerger B and Moreno L and Bouffet E and Upadhyaya SA and André N and Aerts I and Plant-Fox AS and Roughton M and Russo M and Hargrave D},
  year = {2025},
  journal = {Neuro-oncology practice},
  doi = {10.1093/nop/npaf061},
  url = {https://doi.org/10.1093/nop/npaf061}
}

RIS

TY  - JOUR
TI  - Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.
AU  - Geoerger B
AU  - Moreno L
AU  - Bouffet E
AU  - Upadhyaya SA
AU  - André N
AU  - Aerts I
AU  - Plant-Fox AS
AU  - Roughton M
AU  - Russo M
AU  - Hargrave D
PY  - 2025
JO  - Neuro-oncology practice
DO  - 10.1093/nop/npaf061
UR  - https://doi.org/10.1093/nop/npaf061
ER  - 

APA

B, G., L, M., E, B., SA, U., N, A., I, A., AS, P., M, R., M, R., & D, H. (2025). Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.. Neuro-oncology practice. https://doi.org/10.1093/nop/npaf061

Source records